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Abstract - The aim of this study was to investigate distribution of immunophenotypic and cytogenetic features of child-
hood acute leukemia (AL) in the cohort of 239 newly diagnosed patiens registered at the leading pediatric oncohematol-
ogy center in the country during a six-year period (1996-2002). With approximately 60-70% of all childhood AL cases
in Serbia and Montenegro being diagnosed and treated in this institution the used data represent a valid research sample
to draw conclusions for entire country. 
On the basis of five phenotypic markers, the distribution of immunological subtypes was as follows: 169 (70.7%)
expressed B-cell marker CD19 (137 were CD10 positive and 32 CD10 negative), 37 (15.5%) belonged to T-lineage acute
lymphoblastic leukemia (T-ALL) (cyCD3 positive), and 33 (13.8%) were acute myeloblastic leukemia (AML) (CD13
positive and/or CD33 positive in the absence of lymphoid-associated antigens). The ratio of males and females was
1.5:1. Most of the cases were between the ages of 2 and 4, and were predominantly B-lineage acute lymphoblastic
leukemia (B-ALL) cases. Another peak of age distribution was observed at the age of 7. The frequency of T-ALL (18%
of ALL) was similar to that reported for Mediterranean countries: France (19.4%), Greece (28.1%), Southern Italy
(28.3%), and Bulgaria (28.0%). Cytogenetic analyses were performed in 193 patients: 164 ALL and 29 AML. Normal
karyotype was found in 57% of ALL and in 55% of AML patients, while cytogenetic abnormalities including structur-
al, numerical, and complex chromosomal rearrangements were found in 43% of ALL and in 45% of AML patients. Our
results represent a contribution to epidemiological aspects of childhood leukemia studies. 
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INTRODUCTION
The acute leukemias, the most frequent type of childhood
cancer in developed countries, are a heterogenous group
of diseases with regard to type, treatment response, prog-
nosis, and (probably) etiology as well (Parkin et al.
1998; Pui, 1999). This variation, combined with the rel-
ative rarity of the diseases, compromises epidemiological
studies aimed at identifying causal associations. Etiolog-
ical clues could (however) be derived from comparing
national incidence rates. Incidence rates of AL, its age
dependence, and geographic variations within the differ-
ent subgroups might be linked with socioeconomic status
and concomitant exposure to potential leukemogenic
agents (Greaves et al. 1993; Ramotand
Magrath, 1982). As a contribution to such epidemio-
logical studies, we here present systemized data on the
distribution of immunophenotypic and cytogenetic fea-
tures of AL subgroups in Serbia and Montenegro. The
research is based on cases registered at the Department of
Oncohematology's Pediatric Clinic of the Mother and
Child Health Institute of Serbia in Belgrade. The depart-
ment is the leading pediatric oncohematology center in
the country. With approximately 70% of all childhood AL
cases in Serbia and Montenegro being diagnosed and
treated in this institution, the used data represent a valid
research sample from which to draw conclusions for the
entire country.
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PATIENTS AND METHODS
Patients and immunophenotype
From October 1996 to May 2002, AL was diagnosed
in 260 patients admitted to the Mother and Child Health
Institute of Serbia. Immunophenotyping was performed
on a series of 250 previously untreated patients, and suc-
cessful results were obtained in 239 of them. The expres-
sion of CD19, CD10, cytoplasmic CD3 (cyCD3), CD13,
and CD33 antigens was assessed by the alkaline-phos-
phatase/antialkaline-phosphatase (APAAP) method
(Erber et al. 1986; Erberand Mason,1985). All
monoclonal antibodies as well as the APAAP kit were
purchased from Dako (Dakopatts, Glostrup, Denmark).
Morphological, cytochemical, and cytogenetic analyses
All cases met the conventional morphological and
cytochemical criteria (Sudan BB and ANAE) for the
diagnosis and were further classified according to the
FAB system (Van den Does-van den Berg et
al. 1992; Benett et al. 1976). Cytogenetic analysis
was performed on bone marrow cells after direct prepara-
tion and/or unstimulated 24-48 h short-term culture. At
least 20 metaphases were analyzed for each case, using
conventional cytogenetics with GTG banding.
RESULTS
Immunophenotypic studies
The distribution of immunophenotypic subclases
according to age and sex for 239 AL patients is shown in
Table 1. Among them, 169 (70.7%) expressed the B-cell
marker CD19 (137/169 were CD10 positive and 32/169
CD10 negative), 37 (15.5%) belonged to T-ALL (cyCD3
positive), and 33 (13.8%) were AML (Fig. 1). The sub-
class distribution of ALL is reported in Fig. 2: 66.5%
were B-ALL CD10+, 15.5 % were B-ALL CD10-, and
18% were T-ALL. The ratio of males and females is
given in Fig. 3; there were 144 male (60%) and 95 female
(40%), patients, giving a male:female ratio of 1.5:1.
Males predominated in all groups, but the difference is
most striking in T-ALLs (male:female ratio - 3.6:1). For
AML the sex ratio is closer to unity.
Age-related distribution of AL patients
The age distribution is shown in Fig. 4. The median
age for ALL was 5 (range: 4 months to 17 years) and for
AML 7 (range: one day to 16 years). The overall peak of
incidence was between the ages of 2 and 4. This peak was
formed predominantly by B-ALL CD10+, which repre-
sented 87% of all cases in this age group, where another
peak at the age of 7 was observed. After the age of 7, the
proportions of B and T subtypes were similar. The peak
incidence of T-ALL was between the ages of 8 and 13.
We noticed a bimodal distribution of AML with major
peaks at the ages of 1 and 8.
Cytogenetic studies
Cytogenetic analyses were performed in 228/239
(95%) of AL patients: 196/206 (95%) ALL and 32/33
(97%) AML patients. Successful results were obtained in
193/228 (85%) of AL patients: 164/196 (84%) ALL and
29/32 (90%) AML patients (Table 2). Among 164 ALL
patients, a normal karyotype was found in 93/164 (57%)
patients: 57/93 (61%) B-ALL CD10+, 10/93 (11%) B-
ALL CD10-, and 26/93 (28%) T-ALL. We found that
71/164 ALL patients (43%)  had an abnormal  karyotype:
Fig 1. Distribution of immunophenotypes of childhood AL in 239 patiens in Ser-
bia and Montenegro
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Fig. 2. Distribution of immunophenotypes of childhood ALL in 206 patiens in
Serbia and Montenegro
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Table 1.  Age and sex distribution of immunophenotypes of childhood AL in 239 patients in Serbia and Montenegro
Fig. 4. Age-related distribution of childhood AL in 239 patients in Serbia and Montenegro
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Fig. 3. Ratio of males to females in 239 childhood AL patients in Serbia and Montenegro
52/71 (73%) B-ALL CD10+, 13/71 (18%) B-ALL CD10-
and 6/71 (8%) T-ALL. Numerical aberrations were found
in 36/71 (51%) patients: 33/36 (92%) B-ALL CD+, and
3/36 (8%) B-ALL CD-. Among them hyperdiploidy (47-
57) was present in 26/36 patients (24 B-ALL CD10+, 2
B-ALL CD10-); near triploidy (58-80) in 8/36 patients (7
B-ALL CD10+, 1 B-ALL CD10-); and near tetraploidy
(92±) in 2/36 patients with B-ALL CD10+. Structural
aberrations were detected in 18/71 (25%) ALL patients;
and 7/18 (39%) B-ALL CD10+, 10/18 (56%) B-ALL
CD10-, and 1/18 (6%) T-ALL. Among seven B-ALL
CD10+, three patients had t(9;22)(q34;q11); while inv
(1)(p34;q21), del (9)(p13), der (1), and der (3), were pres-
ent in one patient each. In 10 B-ALL CD10-, the follow-
ing structural aberrations were found: t(8;14)(q24;q32),
t(4;11)(q21;q23), t(1;11)(p32;q23), and t(13;19)(q14;
p13), one patient each; dup (1)(q21; q32) in two patients;
and  der  (1), der (9), der (18),  and der 19 in one patient
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each. In one T-ALL patient, del(11)(q23) was found.
Complex chromosomal rearrangements with the presence
of numerical and structural aberrations either in one or in
different clones were detected in 17/71 (24%) ALL
patients: 12/17 (71%) B-ALL CD10+, and five (29%) T-
ALL. Among 12 B-ALL CD10+ patients, one patient had
two Ph"S chromosomes in two clones and the other ones
t(9;22)(q34;q11), together with other nonspecific struc-
tural and numerical chromosomal aberrations;
t(1;14)(p32;q11) was found in one clone of the patient
with T-ALL and t(11;14)(p13;q11) in other patients with
T-ALL and complex karyotype (Table 1).
Among 29 AML patients, a normal karyotype was
found in 16 (55%) and an abnormal karyotype in 13
(45%) patients. Structural aberrations were observed in
7/13 (54%) patients with AML: t(15;17)(q22;q11), in two
patients; and t(1;3)(p12;q13), inv(16)(p13;q22),
inv(7)(p22;q22), del(2)(q33), and del(9)(q22) in one
patient each. Among 6/13 (46%) AML patients with co-
mplex chromosomal rearrangements, t(15;17)(q22;q11)
was found in two clones of one patient and
t(8;21)(q22;q22) in one clone of the other patients (Table
1), together with other uncommon chromosome anom-
alies.
DISCUSSION
In the present study we have analyzed the
immunophenotype of 239 patients and cytogenetic fea-
tures of 228 patients with childhood AL referred to a sin-
gle institution in Serbia and Montenegro. Our series
allowed us to draw conclusions about the distribution of
childhood AL in the entire country, as 60-70% of child-
hood acute leukemia cases from all regions were treated
in this clinic.
The majority of cases (71%) were precursor B-ALL
(either CD10+ or CD10-). The age distribution showed a
clear peak between the ages of 2 and 4 with a predomi-
nance of precursor B-ALL CD10+. The results on age
and sex distribution and phenotypic pattern of our
patients were in agreement with those reported by other
authors for Caucasian children (Parkin et al. 1998;
Greaveset al. 1993). However, some differences were
observed. First, the precursor B-ALL CD10+ displays a
peak of age distribution at the age of 7, which does not
fully correspond to the data from either developed or
undeveloped countries. It is well documented in previous
studies that earlier in the 20th century in developed coun-
tries there was an earlier appearance of the 2-5 year peak
of ALL, as there was some positive association between
socio-economic status and ALL incidence (Erberand
Mason, 1985). The typical 2-5 year peak is evident in
Serbia and Montenegro, but  there is a higher frequency
of patients of  age 5-10 and ‡10 than was observed in
developed countries (Malta et al. 1997). Secondly, our
results indicate that the proportion of T-ALL (18%) is
between the groups of countries with low and moderate
proportion of T-ALL (Papamichail et al. 1985;
Taskov et al. 1995; Russo1985). We could not
ascertain it fully, but our assumption is that our findings
could be explained by influence of environmental fac-
tors: socio-economic development and concomitant
exposure to potential leukemogenic agents (Greaves
et al. 1993; Ramot andMagrath, 1982). The socio-
economic circumstances in the region (West Balkans) are
important for the proper interpretation of this study's
results. This region has always been relatively
underdeveloped  by  European standards,  but  the  socio-
Table 2. Cytogenetic findings in 193 children with AL from Serbia and Montenegro
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economic situation dramatically deteriorated from the
beginning of the 1990s and the outbreak of the wars for
the Yugoslav succession. The already grave humanitarian
situation was additionaly complicated by significant
demographic changes: Serbia was flooded by almost one
million refugees from Serbian-populated regions of
Croatia and Bosnia and Herzegovina and internally dis-
placed persons from Kosovo and Metohija. An addition-
al factor that remains to be carefully monitored and
researched is the potential influence of toxic substances
the population was exposed to during the war devasta-
tions (e.g., depleted uranium and spills from bombed-out
chemical industrial facilities and oil refineries). We plan
to collect  detailed epidemiological data and characterize
time trends in the age- and sex-specific incidence of
childhood AL in the future. Such epidemiological studies
have already been done in developed countries (Hjal-
grim et al. 2003). 
Cytogenetic abnormalities, both lymphoblastic and
myeloid, are common in patients with AL, and some of
these have prognostic significance. The most frequent
translocations in ALL are: t(1;19), t(4;11), others involv-
ing the 11q23 breakpoint, and t(9;22) in B-ALL; t(8;14),
t(2;8), and t(8;22) in ALL with L3 morphology; and
t(11;14) and (1;14) in T-ALL. In the group of 35/164
ALL with structural (18 cases) and complex (17 cases)
chromosomal rearrangments, common translocations
were found in nine cases: 7 B-ALL [t(9:22) in five cases;
t(8;14) in one case;  t(4;11) in one case] and 2 T-ALL
[t(1;14) in one case and t(11;14) in one case]. In the
remaining 26 ALL patients, non-specific structural aber-
rations (translocations, inversions, deletions, and dupli-
cations) involving chromosomes 1, 9, 3, 19, and 18, were
found. Some of the common translocations described
above are recognized as predictive of outcome: t(9;22) is
present in approximately 3%-4% of pediatric ALL
patients having an unfavorable prognosis, which is in line
with our results describing five cases of t(9;22) in the
group of 164 ALL patients (3%) (Hann et al. 2001;
Arico et al. 2000; Schrappe et al. 1998; Ribeiro
et al. 1997); t(4;11) and others involving 11q23 occur in
approximately 4% of cases, which usually show a poor
response to initial therapy (Rubnitzand Pui, 1987;
Rubnitzand Look, 1998). In the analyzed group of
164 ALL, these translocations were found in 2/164 ALL
cases, both having B-ALL phenotype (1%). Hyper-
diploidy (>50 chromosomes per cell or DNA index>1.16)
occurs in 20% to 25% of cases of B-precursor ALL, but
very rarely in cases of T-cell ALL (Puiand Evans,
1998) and is associated with a favorable prognosis. In our
group of 164 ALL patients, hyperdiploidy (47-57 chro-
mosomes) was found in 26/164 cases (16%) both  B cell
lineage ALL. In eight  cases of B-ALL near triploidy (58-
80 chromosomes) was found and in 2 other cases of B-
ALL near tetraploidy (92± chromosomes) was observed.
The most frequent cytogenetic abnormalities in
childhood AML are: t(8;21), t(15;17), and inv(16); mono-
somy 5/5q, 7/7q, and 17p abnormalities are classified as
unfavorable. In the group of 13/29 AML patients with
structural (seven cases) and complex (six cases) chromo-
somal rearrangements, common chromosomal abnormal-
ities were observed in six cases: t(15;17) in three cases,
and t(8;21) and inv(16) in one patient each. In the
remaining seven AML patients, non-specific chromoso-
mal rearrangements (tranlocations, inversions, deletions,
and complex rearrangements) involving chromosomes 1,
3, 7, and 9 were observed. Some of the common chromo-
somal abnormalities in AML have prognostic signifi-
cance: translocations (8;21) (Hann et al. 2001;
Schrappe et al. 1998) and inv(16) account for 5%-
12%, 5%-8%, and 10%-12% of AML cases and are asso-
ciated with good prognosis and favorable response to
therapy (Brunning et al. 2001; Byrd et al. 2002;
Bloomfield et al. 2002; Mrozek  et al. 1997;
Marlton et al. 1995). In this series of 29 AML
patients, these chromosomal aberrations were found in
3% (t 8/21), 10% (t 15/17), and  3% (inv16) of the cases.
The difference in proportion of common chromosomal
aberrations in our series, may be attributable to the small
number of AML patients evaluated for cytogenetics. 
We started flow cytometric immunophenotyping of
childhood AL in 2002. Today, we have a well document-
ed diagnostics for the entire nation (until November 2002
about 10-20% of the population was not covered). We
expect to have complete national data for imunopheno-
type and cytogenetic features of childhood AL in the near
future.   
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1Институт за здравствену заштиту мајке и детета Србија “Др Вукан Чупић”, 
11000 Београд, Србија и Црна Гора,
2Медицински факултет, Универзитет у Београду, 11000 Београд, Србија и Црна Гора,
3Биолошки факултет, Универзитет у Београду, 11000 Београд, Србија и Црна Гора
У  Институту  за  здравствену  заштиту  мајке  и
детета Србије, у периоду од октобра 1996. године до
маја 2002. године, дијагноза акутне леукемије (AL)
постављена је код 239 болесника. Циљ овог рада је
утврђивање распрострањености имуно-фенотипских
и  цитогенетских  особина ALкод  деце  из  Србије  и
Црне Горе. На основу анализе 4 фенотипских маркера
утврђена  је  распрострањеност  имунолошких
подтипова  ове  болести.  Дијагноза  акутне
лимфобластне B леукемије (ALL-B) потврђена је код
169 (70.7%) болесника (137 CD19 позитивни, CD10
негативни и 32 CD19 позитивни, CD10 негативни),
затим ALL-T (cyCD3  позитиван)  код 37 (15.5%)
болесника  и AML (CD13  позитивни  и/или CD33
позитивни  уз  истовремено  одсуство  антигена
карактеристичних за лимфоидну ћелијску  лозу) код
33 (13.8%). Однос дечака према девојчицама био је
1.5:1.  Већина  болесника  била  је  узраста од 2  до 4
године  и  припадала  је ALL-B  подтипу  леукемије.
Други,  нешто  нижи  врх  учесталости ALL-B
забележен је у узрасту од 7 година. Учесталост ALL-
T  од 18% ( од  укупног  броја ALL)  је  слична
учесталости у медитеранским земљама: Француској
(19.4%),  Грчкој (28.1%),  јужној  Италији (28.3%)  и
Бугарској (28%).  Цито-генетичке  анализе  извршене
су код 193 болесника: 164 ALL и 29 AML. Нормалан
кариотип  доказан  је  код 57% ALL  и 55% AML.
Цитогенетске  аберације,  укључујући  и  нумеричке,
структурне  и  комплексне,  откривене  су  код 43%
оболелих од ALL  и 45%  оболелих од AML. Наши
резултати  представљају допринос епидемиолошким
аспектима проучавања акутних леукемија код деце.
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